Vascular-targeting agent
A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.[1]
VTAs can be small-molecule or ligand-based.
Small-molecule VTAs include:
- microtubule destabilizing drugs such as combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503
- vadimezan (ASA404)
Clinical trials
Phase II : ZD6126, CA4P, NPI-2358[2]
Phase III : DMXAA (ASA404).
References
- ^ "Vascular Targeting Agents as Cancer Therapeutics" (PDF). 2004.
{{cite journal}}: Cite journal requires|journal=(help) - ^ Conducted by Nereus Pharmaceuticals.
Staff (2009). "Clinical Trials Update". Genetic Engineering & Biotechnology News. 29 (8): 58Template:Inconsistent citations{{cite journal}}: CS1 maint: postscript (link)
 | This article has not been added to any content categories. Please help out by adding categories to it so that it can be listed with similar articles, in addition to a stub category. (September 2010) |
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |